LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC announces that it is investigating Endo International plc (“Endo” or the “Company”) (Nasdaq: ENDP) concerning reports that the Company unlawfully colluded with other companies to fix generic drug prices.
If you purchased or otherwise acquired Endo shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
Bloomberg News reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Mylan NV, Teva Pharmaceutical Industries Ltd., Allergan Plc, Lannett Co., Impax Laboratories Inc., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo International plc and Taro Pharmaceutical Industries Ltd. When this news was announced, shares of Endo fell in value.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.